Perspectives in melanoma

Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Carlo Bifulco, Gerardo Botti, Corrado Caracò, Gennaro Ciliberto, Michael A. Davies, Reinhard Dummer, Soldano Ferrone, Thomas F. Gajewski, Claus Garbe, Jason J. Luke, Francesco M. Marincola, Giuseppe Masucci, Janice M. Mehnert, Nicola Mozzillo, Giuseppe Palmieri, Michael A. Postow, Stephen P. Schoenberger & 2 others Ena Wang, Magdalena Thurin

Research output: Contribution to journalArticle

Abstract

Metastatic melanoma represents a challenging clinical situation and, until relatively recently, there was an absence of effective treatment options. However, in 2011, the advanced melanoma treatment landscape was revolutionised with the approval of the anti-cytotoxic T-lymphocyte-associated protein-4 checkpoint inhibitor ipilimumab and the selective BRAF kinase inhibitor vemurafenib, both of which significantly improved overall survival. Since then, availability of new immunotherapies, especially the anti-programmed death-1 checkpoint inhibitors, as well as other targeted therapies, have further improved outcomes for patients with advanced melanoma. Seven years on from the first approval of these novel therapies, evidence for the use of various immune-based and targeted approaches is continuing to increase at a rapid rate. Improved understanding of the tumour microenvironment and tumour immuno-evasion strategies has resulted in different approaches to target and harness the immune response. These new immune-based approaches offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as targeted therapy, electrochemotherapy and surgery. The increasing number of treatment options that are now available has resulted in a growing need to identify which patients will derive most benefit from which treatments. Much research is now focused on the identification of biomarkers that can be utilised to help select patients for treatment. These and other recent advances in the management of melanoma were the focus of discussions at the third Melanoma Bridge meeting (30 November-2 December, 2017, Naples, Italy), which is summarised in this report.

Original languageEnglish
Article number207
JournalJournal of Translational Medicine
Volume16
Issue number1
DOIs
Publication statusPublished - Jul 21 2018

Fingerprint

Italy
Tumors
Melanoma
Proto-Oncogene Proteins B-raf
T-cells
Biomarkers
Surgery
Availability
Therapeutics
Proteins
Electrochemotherapy
Tumor Microenvironment
Cytotoxic T-Lymphocytes
Immunotherapy
PLX4032
ipilimumab
Survival
Research
Neoplasms

Keywords

  • Biomarkers
  • Combination strategies
  • Immunotherapy
  • Melanoma
  • Target therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Ascierto, P. A., Puzanov, I., Agarwala, S. S., Bifulco, C., Botti, G., Caracò, C., ... Thurin, M. (2018). Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). Journal of Translational Medicine, 16(1), [207]. https://doi.org/10.1186/s12967-018-1568-6

Perspectives in melanoma : Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). / Ascierto, Paolo A.; Puzanov, Igor; Agarwala, Sanjiv S.; Bifulco, Carlo; Botti, Gerardo; Caracò, Corrado; Ciliberto, Gennaro; Davies, Michael A.; Dummer, Reinhard; Ferrone, Soldano; Gajewski, Thomas F.; Garbe, Claus; Luke, Jason J.; Marincola, Francesco M.; Masucci, Giuseppe; Mehnert, Janice M.; Mozzillo, Nicola; Palmieri, Giuseppe; Postow, Michael A.; Schoenberger, Stephen P.; Wang, Ena; Thurin, Magdalena.

In: Journal of Translational Medicine, Vol. 16, No. 1, 207, 21.07.2018.

Research output: Contribution to journalArticle

Ascierto, PA, Puzanov, I, Agarwala, SS, Bifulco, C, Botti, G, Caracò, C, Ciliberto, G, Davies, MA, Dummer, R, Ferrone, S, Gajewski, TF, Garbe, C, Luke, JJ, Marincola, FM, Masucci, G, Mehnert, JM, Mozzillo, N, Palmieri, G, Postow, MA, Schoenberger, SP, Wang, E & Thurin, M 2018, 'Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)', Journal of Translational Medicine, vol. 16, no. 1, 207. https://doi.org/10.1186/s12967-018-1568-6
Ascierto, Paolo A. ; Puzanov, Igor ; Agarwala, Sanjiv S. ; Bifulco, Carlo ; Botti, Gerardo ; Caracò, Corrado ; Ciliberto, Gennaro ; Davies, Michael A. ; Dummer, Reinhard ; Ferrone, Soldano ; Gajewski, Thomas F. ; Garbe, Claus ; Luke, Jason J. ; Marincola, Francesco M. ; Masucci, Giuseppe ; Mehnert, Janice M. ; Mozzillo, Nicola ; Palmieri, Giuseppe ; Postow, Michael A. ; Schoenberger, Stephen P. ; Wang, Ena ; Thurin, Magdalena. / Perspectives in melanoma : Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). In: Journal of Translational Medicine. 2018 ; Vol. 16, No. 1.
@article{37e73cf0984543009267c88a27e5be2f,
title = "Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)",
abstract = "Metastatic melanoma represents a challenging clinical situation and, until relatively recently, there was an absence of effective treatment options. However, in 2011, the advanced melanoma treatment landscape was revolutionised with the approval of the anti-cytotoxic T-lymphocyte-associated protein-4 checkpoint inhibitor ipilimumab and the selective BRAF kinase inhibitor vemurafenib, both of which significantly improved overall survival. Since then, availability of new immunotherapies, especially the anti-programmed death-1 checkpoint inhibitors, as well as other targeted therapies, have further improved outcomes for patients with advanced melanoma. Seven years on from the first approval of these novel therapies, evidence for the use of various immune-based and targeted approaches is continuing to increase at a rapid rate. Improved understanding of the tumour microenvironment and tumour immuno-evasion strategies has resulted in different approaches to target and harness the immune response. These new immune-based approaches offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as targeted therapy, electrochemotherapy and surgery. The increasing number of treatment options that are now available has resulted in a growing need to identify which patients will derive most benefit from which treatments. Much research is now focused on the identification of biomarkers that can be utilised to help select patients for treatment. These and other recent advances in the management of melanoma were the focus of discussions at the third Melanoma Bridge meeting (30 November-2 December, 2017, Naples, Italy), which is summarised in this report.",
keywords = "Biomarkers, Combination strategies, Immunotherapy, Melanoma, Target therapy",
author = "Ascierto, {Paolo A.} and Igor Puzanov and Agarwala, {Sanjiv S.} and Carlo Bifulco and Gerardo Botti and Corrado Carac{\`o} and Gennaro Ciliberto and Davies, {Michael A.} and Reinhard Dummer and Soldano Ferrone and Gajewski, {Thomas F.} and Claus Garbe and Luke, {Jason J.} and Marincola, {Francesco M.} and Giuseppe Masucci and Mehnert, {Janice M.} and Nicola Mozzillo and Giuseppe Palmieri and Postow, {Michael A.} and Schoenberger, {Stephen P.} and Ena Wang and Magdalena Thurin",
year = "2018",
month = "7",
day = "21",
doi = "10.1186/s12967-018-1568-6",
language = "English",
volume = "16",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Perspectives in melanoma

T2 - Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

AU - Ascierto, Paolo A.

AU - Puzanov, Igor

AU - Agarwala, Sanjiv S.

AU - Bifulco, Carlo

AU - Botti, Gerardo

AU - Caracò, Corrado

AU - Ciliberto, Gennaro

AU - Davies, Michael A.

AU - Dummer, Reinhard

AU - Ferrone, Soldano

AU - Gajewski, Thomas F.

AU - Garbe, Claus

AU - Luke, Jason J.

AU - Marincola, Francesco M.

AU - Masucci, Giuseppe

AU - Mehnert, Janice M.

AU - Mozzillo, Nicola

AU - Palmieri, Giuseppe

AU - Postow, Michael A.

AU - Schoenberger, Stephen P.

AU - Wang, Ena

AU - Thurin, Magdalena

PY - 2018/7/21

Y1 - 2018/7/21

N2 - Metastatic melanoma represents a challenging clinical situation and, until relatively recently, there was an absence of effective treatment options. However, in 2011, the advanced melanoma treatment landscape was revolutionised with the approval of the anti-cytotoxic T-lymphocyte-associated protein-4 checkpoint inhibitor ipilimumab and the selective BRAF kinase inhibitor vemurafenib, both of which significantly improved overall survival. Since then, availability of new immunotherapies, especially the anti-programmed death-1 checkpoint inhibitors, as well as other targeted therapies, have further improved outcomes for patients with advanced melanoma. Seven years on from the first approval of these novel therapies, evidence for the use of various immune-based and targeted approaches is continuing to increase at a rapid rate. Improved understanding of the tumour microenvironment and tumour immuno-evasion strategies has resulted in different approaches to target and harness the immune response. These new immune-based approaches offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as targeted therapy, electrochemotherapy and surgery. The increasing number of treatment options that are now available has resulted in a growing need to identify which patients will derive most benefit from which treatments. Much research is now focused on the identification of biomarkers that can be utilised to help select patients for treatment. These and other recent advances in the management of melanoma were the focus of discussions at the third Melanoma Bridge meeting (30 November-2 December, 2017, Naples, Italy), which is summarised in this report.

AB - Metastatic melanoma represents a challenging clinical situation and, until relatively recently, there was an absence of effective treatment options. However, in 2011, the advanced melanoma treatment landscape was revolutionised with the approval of the anti-cytotoxic T-lymphocyte-associated protein-4 checkpoint inhibitor ipilimumab and the selective BRAF kinase inhibitor vemurafenib, both of which significantly improved overall survival. Since then, availability of new immunotherapies, especially the anti-programmed death-1 checkpoint inhibitors, as well as other targeted therapies, have further improved outcomes for patients with advanced melanoma. Seven years on from the first approval of these novel therapies, evidence for the use of various immune-based and targeted approaches is continuing to increase at a rapid rate. Improved understanding of the tumour microenvironment and tumour immuno-evasion strategies has resulted in different approaches to target and harness the immune response. These new immune-based approaches offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as targeted therapy, electrochemotherapy and surgery. The increasing number of treatment options that are now available has resulted in a growing need to identify which patients will derive most benefit from which treatments. Much research is now focused on the identification of biomarkers that can be utilised to help select patients for treatment. These and other recent advances in the management of melanoma were the focus of discussions at the third Melanoma Bridge meeting (30 November-2 December, 2017, Naples, Italy), which is summarised in this report.

KW - Biomarkers

KW - Combination strategies

KW - Immunotherapy

KW - Melanoma

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85050278651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050278651&partnerID=8YFLogxK

U2 - 10.1186/s12967-018-1568-6

DO - 10.1186/s12967-018-1568-6

M3 - Article

VL - 16

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 207

ER -